Seeking Alpha

Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of...

Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of elagolix, a treatment for endometriosis, which is a debilitating gynecological disease that affects around 100M women worldwide and can cause infertility. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs